4564 ONCOTHERAPY SCIENCE
- 15
- 00.00%
ONCOTHERAPY SCIENCE News
Modalis, GRCS, etc. [5% rule for emerging markets]
＜4175＞COLY Co., Ltd. Daichi Sasaki Stock Ownership Ratio 7.50% → 7.20% Reporting Obligation Date 2023/09/08＜4477＞BASE Co., Ltd. Tsuruoka Yuta Stock Holding Ratio 16.15% → 17.20% Reporting Obligation Occurrence Date 2024/05/09 ＜4564＞Oncotherapy Science Co., Ltd. Long Corridor Asset Management Limited (Long Corridor Asset M)
Human T, Cygenia, etc.
＜2160＞Preparing to apply for a market classification change to the GNI Tokyo Stock Exchange Prime Market signed a business alliance (strategic partnership agreement) with Governance Partners, which handles the recruitment and management of investment funds Ortz, which handles P.A.I. (personal artificial intelligence) research and development, etc., established a joint venture with Governance Partners ＜3691＞Digital Plus earnings forecast revised, operating profit forecast 0.25 billion yen ←△ 102 million yen ＜4068＞Basis Downward revisions, current operating profit
ONCOTHERAPY SCIENCE: Financial Results for the Fiscal Year Ending March 31, 2024 [Japanese Standards] (Consolidated)
OncoTherapy Science FY Loss Y1.29B Vs Loss Y1.12B
OncoTherapy Science Inc. (4564.TO) Japan Year Ended March 31 GROUP 2024 2023 Revenue Y610.00 mln Y1.13 bln Operating Profit (Y1.12 bln) (Y1.
ONCOTHERAPY SCIENCE: Notice regarding the difference between consolidated results for the fiscal year ending 2024/3 and the results for the previous fiscal year
Iole, TKP, etc.
＜157A＞Green Monster Co., Ltd. Ogawa Ryo Stock Ownership Ratio 34.80% → 34.80% Reporting Obligation Date 2024/04/26 ＜2334＞Iole Co., Ltd. Sumitomo Mitsui DS Asset Management Co., Ltd. Stock Ownership Ratio 7.50% → 6.01% Reporting Obligation Date 2024/04/30 ＜2586＞Fruta Fruta Co., Ltd. Rakuten Securities Co., Ltd. Stock Ownership Ratio 5.61% → 4.60% Report
Shinka, Material Group, etc.
＜149A＞Shinka SBI Investment Co., Ltd. Stock Ownership Ratio 7.91% → 10.84% Reporting Obligation Date 2024/04/25 ＜156A＞Material Group TenX Investment LTD Co., Ltd. (10X Investment LTD.) Stock Ownership Ratio 11.46% → 10.20% Reporting Obligation Date 2024/04/25 ＜156A＞Material Group Shares
The Tokyo Stock Exchange Growth Index rebounded drastically, and even though poor sales continued, there was a strong rise similar to Prime
TSE Growth Market Index 840.73 +15.26/ Volume 880.4 million shares/ trading price 87.9 billion yen TSE Growth Market 250 Index 656.31 +13.35 /turnover 77.76 million shares/ trading price 76.5 billion yen Today's growth market rebounded sharply in both the TSE Growth Market Index and the TSE Growth Market 250 Index. The number of rising stocks is 411, the number of falling stocks is 136, and unchanged is 28. The US stock market continued to rise on the 6th. The Dow Jones Industrial Average rose by $176.59 (+0.4)
Media Research Institute, 3D Matrix, etc.
＜4564＞Number of shares issued from mass exercise of the 36th OTS Stock Acquisition Rights (with exercise price amendment clause), 6 million shares ＜4586＞number of shares issued from mass exercise 1 of the 28th Medlec Stock Acquisition Rights (with exercise price correction clauses), 600,000 shares ＜5256＞FusicAI training systems sold ＜7777＞3D Matrix TDM-623 Apply for approval<9242
Jade Group, Digital Plus, etc.
＜3558＞Jade Group Co., Ltd. Asset Value Investors Limited (AssetValue Investors Limited) Stock Ownership Ratio 8.33% → 9.43% Reporting Obligation Date 2024/04/18 ＜3691 ＞Digital Plus McCauley Bank Limited Stock Ownership Ratio 15.79% → 14.54% Reporting Obligation Date 2024/04/09＜426
FINATEXT, TASKI HD, etc.
＜166a＞Acquired shares of Aura, which handles the TASKI HD Asset Consulting business, and made it a subsidiary ＜4419＞FinATEXT upward revision, previous fiscal year operating profit forecast 220 million yen ← 0.21 billion yen ＜4564＞OTS acquisition/cancellation of all remaining 35th stock acquisition rights (with exercise price correction clauses) ＜4586＞Medlec 28th Stock Acquisition Rights (with exercise price correction clauses) from the 11th, 570,000 shares ＜4597＞Number one 14th Stock Acquisition Rights (exercise)
Tsubota Lab, 3D Matrix, etc.
＜2173＞Hakuten Shareholder Benefit System Changed (Expanded) ＜4564＞Acquisition and Cancellation of All Remaining Stock Acquisition Rights (with Exercise Price Amendment Clauses) of OTS 36th Stock Acquisition Rights Issuance of 36th Stock Acquisition Rights (54 million potential shares, procurement amount approximately 1,029 billion yen) ＜4890＞Tsubota Lab Pipeline “TLG-005” completed inclusion of subjects in specific clinical research on mild dementia (MCI) ＜7777＞3D matrix hemostasis material “purestat” To the surgical field Physicians-led efforts to expand adaptation
OncoTherapy Science 9-Mos Loss Y987.00M Vs Loss Y913.00M
OncoTherapy Science Inc. (4564.TO) Japan Nine Months Ended December 31 GROUP 2023 2022 Revenue Y466.00 mln Y699.00 mln Operating Profit
OncoTherapy Science 1H Loss Y710.00M Vs Loss Y613.00M
OncoTherapy Science Inc. (4564.TO) Japan 1st Half Ended September 30 GROUP 2023 2022 Revenue Y356.00 mln Y514.00 mln Operating Profit (Y
OncoTherapy Science 1Q Loss Y400.00M Vs Loss Y277.00M
OncoTherapy Science Inc. (4564.TO) Japan 1st Quarter Ended June 30 GROUP 2023 2022 Revenue Y148.00 mln Y385.00 mln Operating Profit (Y38
OncoTherapy Science FY Loss Y1.12B Vs Loss Y2.57B
OncoTherapy Science Inc. (4564.TO) Japan Year Ended March 31 GROUP 2023 2022 Revenue Y1.13 bln Y1.15 bln Operating Profit (Y1.11 bln)
OncoTherapy Science 9-Mos Loss Y913.00M Vs Loss Y2.14B
OncoTherapy Science Inc. (4564.TO) Japan Nine Months Ended December 31 GROUP 2022 2021 Revenue Y699.00 mln Y335.00 mln Operating Profit
Analysis
Price Target
No Data
